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Imatinib mesylate in the treatment of newly
diagnosed or refractory/resistant c-KIT positive
acute myeloid leukemia. Results of an italian
multicentric phase II study.
We evaluated safety and efficacy of imatinib (600
mg) in 36 c-KIT+ acute myeloid leukemia patients
not amenable to receive conventional chemothera-
py. No patient achieved complete remission. One
patient obtained a hematologic improvement
(platelet increase with transfusion independence).
Median overall survival was 3 months (0.5-44+).
Non-hematologic toxicity was overall mild.
Haematologica 2007; 92:1721-1722. DOI: 10.3324/haematol.11345
The treatment of poor risk acute myeloid leukemia
(AML), including elderly patients or those with poor per-
formance status, or with refractory/relapsed disease,
remains problematic due to the scarce efficacy and high
toxicity of conventional chemotherapy.1-5
We investigated the efficacy and toxicity of imatinib in
c-KIT+ AML cases. Some authors reported responses in c-
KIT+ AML and high-risk myelodysplastic syndromes
(MDS).6,7 Nevertheless, whether c-KIT was the actual tar-
get in such cases is still unclear. The primary end-point
was the response rate assessment. The secondary end-
points were CR duration, overall survival at 12 months
and type, frequency, severity, timing, and relatedness of
adverse events (AE).
Thirty-six c-KIT+ AML patients not amenable to con-
ventional chemotherapy were enrolled in an open label
phase II study. Patients aged over 18 years, with any FAB
but M3 AML refractory or relapsed after conventional
chemotherapy, as well as patients with previously
untreated AML not conventional chemotherapy were eli-
gible, provided that at least one of the known imatinib
targets, PDGFR α or β, c-KIT (assessed by flow-cytome-
try) or BCR-ABL1 (assessed by RT-PCR) was expressed.
No core-binding-factor positive patients were enrolled.
Treatment consisted of imatinib mesylate at the initial
dose of 100 mg/day. If no major toxicity was observed,
imatinib dosage was increased every second day up to a
maximum of 800 mg/day. Therapy was assumed for at
least two months and continued if a clinical response was
observed. In cases of clear progression, the treatment
could be withdrawn at any time at the physician’s discre-
tion. Clinical response was evaluated according to con-
ventional criteria.8
All the 36 enrolled patients were evaluated for
response. Only 1 out of 36 patients obtained a clinical
response. She showed a hematologic improvement, with
transient platelet increase and temporary transfusion
independence. Conversely, Hb, WBC count and bone
marrow blasts did not significantly improve. The clinical
benefit lasted for approximately 4 months (Figure 1A).
Intriguingly, this patient was the only one with expres-
sion of PDGFRB. While under treatment, blast cells pro-
gressively became PDGFRB negative, until progression
occurred (Figure 1). On the contrary, CD117 was
expressed and phosphorylated during the entire treat-
ment duration. None of the other 35 patients (97%)
responded. Of these patients, 21 (62%) and 7 (21%)
interrupted imatinib for disease progression and adverse
events respectively. Six out of 36 patients (17%) died dur-
ing imatinib therapy, due to cerebral hemorrhagic stroke
(2), disease progression (2) and multi organ failure (2).
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Figure 1. A. Platelet count improvement in the single responder was associated with CD140 (PDGFRB) expression but not with c-KIT phos-
phorylation. p-CD117: phosphorylated c-KIT (assessed by flow cytometry). B. Hb and WBC count as well as ANC and blast percentage did
not significantly vary during treatment. C. Extra-hematologic treatment toxicity (WHO scale). D. Overall survival of patient population. Kaplan-
Meier Cumulative Survival Plot for OS (months); Censor Variable: death.
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The median treatment duration was 31 days (range
2–311), at a median dosage of 600 mg/day (range
200–800). Only 53% of patients assumed imatinib for at
least 4 weeks. The other patients withdrew from the
study within 4 weeks of therapy due to disease progres-
sion, or died within this period while on therapy. The
median overall survival was 3 months (0.5-44+) (Figure
1B). Imatinib was overall well tolerated. Treatment out-
come and toxicity are summarized in Table 1 and Figure
1C respectively.
The effect of imatinib on AML and myelodysplastic
syndromes was previously evaluated in other studies.
Kindler et al., reported 5/21 clinical responses, including
2 CR.7 However, the study population was slightly differ-
ent from ours and clinical responses were observed in
patients with limited marrow/peripheral blood involve-
ment.7 Furthermore, CR was only achieved in patients
starting imatinib during hematopoietic reconstitution
after chemotherapy. In some instances, responses were
recorded after prolonged imatinib administration, a rare
event in our series. In another study, Cortes and
Colleagues obtained results more similar to our own.6
However, whether c-KIT is not a good candidate as
therapeutic target in AML or whether imatinib was not
able to completely inhibit its function is not known. It is
unlikely, however, that D816- c-KIT mutations played a
role since these are rare in unselected AML. In our series,
responses were not observed despite c-KIT de-phospho-
rylation during treatment, while the single responder
showed p-CD117+ when PLT count increased.
Furthermore, other possible targets may be relevant in
AML rather than c-KIT, including c-FMS which can be
inhibited by imatinib.9,10 On the other hand, the biologic
and clinical role of PDGFRB inhibition should also be fur-
ther investigated in AML. 
We conclude that imatinib is not effective as single
agent in the treatment of c-KIT+ AML, though further
studies might indicate possible indications in specific
AML subsets. 
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Table 1. Treatment and outcome.
Treatment duration
Median (days, range) 31 (2-311)
≤2 weeks 2 (5.6%)
2-4 weeks 6 (17.6%)
4-8 weeks 8 (23.5%)
≥ 8 weeks 10 (29.4%)
Median treatment dosage (mg, range) 600 (200-600)
Clinical response
Complete response 0
Hematologic improvement 1
No response 35
Stable disease 1
Progression 21
Death during treatment 6
Withdrawn due to toxicity 7
Causes of death during treatment
Multi-organ failure 2
Leukemic progression 2
CNS hemorrhage 2
Median overall survival, months (range) 3 (0.5-44+)
